2181.HK - Mabpharm Limited

HKSE - HKSE Delayed Price. Currency in HKD

Mabpharm Limited

Block G79
Lujia Road East Koutai Road West China Medical City
Taizhou 225300


Full Time Employees262

Key Executives

NameTitlePayExercisedYear Born
Mr. Yunfeng LiExec. Director & Chief Financial OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Mabpharm Limited, a biopharmaceutical company, focuses on the research, development, and production of drugs and biosimilar drugs for cancers and autoimmune diseases in China. The company's products under the Phase III clinical trial include CMAB007, a recombinant humanized anti-IgE monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for moderate to severe active rheumatoid arthritis. It is also developing CMAB819 that is in Phase I clinical trial for the treatment of metastatic non-small cell lung cancer and hepatocellular carcinoma; CMAB809 that is in Phase I clinical trial for the treatment of HER2 overexpressing breast cancer or metastatic gastric cancer; CMAB815 for the treatment of rheumatoid arthritis; CMAB810 for the treatment of breast cancer; CMAB813 for the treatment of severe lower respiratory tract disease in pediatric patients; and CMAB816 for the treatment of periodic fever syndrome and systemic juvenile idiopathic arthritis. The company was founded in 2018 and is headquartered in Taizhou, China. Mabpharm Limited is a subsidiary of Asia Mabtech Limited.

Corporate Governance

Mabpharm Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.